⌕
Arcutis Biotherapeutics · ARQT · Nasdaq
Tenet 43 · Weak
Compare
$27.33+0.66%At closeTenet 43 · Weak
$27.33+0.18 (+0.66%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Arcutis Biotherapeutics (ARQT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ARQT's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Defense WorldNov 17, 2026 · 08:00 ETEARNINGS EXPECTED BY FEB 24
Arcutis Biotherapeutics, Inc. $ARQT Stock Bought by Aberdeen Group plc

Aberdeen Group plc grew its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) by 9.7% in a recent quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,2…

ARQT +0.7% todayRead at source ↗
● GlobeNewsWireNov 13, 2026 · 09:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 24
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting

New INTEGUMENT-INFANT trial results demonstrate improvements in itch, reductions in symptoms, and improvements in quality of life for infants with atopic dermatitis and their families Findings further support investigati…

ARQT +0.7% todayRead at source ↗
● Defense WorldNov 7, 2026 · 05:35 ET
Arcutis Biotherapeutics (NASDAQ:ARQT) EVP Sells $1,372,800.00 in Stock

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) EVP Masaru Matsuda sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $34…

ARQT +0.7% todayRead at source ↗
● GlobeNewsWireNov 6, 2026 · 16:00 ETCOMPANY'S OWN WORDS
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, t…

ARQT +0.7% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis

New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis Study aims to expand once-daily ZORYVE cream treatment …

ARQT +0.7% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 23:14 ETEARNINGS EXPECTED BY FEB 24
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. ( ARQT ) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Company Participants Brian Schoelkopf - Head of Investor Relations Todd Watanabe - President, CEO & Director Robert Lisicki - Inte…

ARQT +0.7% todayRead at source ↗
● MarketBeatNov 4, 2026 · 19:19 ETEARNINGS EXPECTED BY FEB 24
Arcutis Biotherapeutics Q3 Earnings Call Highlights

Arcutis Biotherapeutics NASDAQ: ARQT raised its full-year 2026 net revenue guidance after third-quarter sales of its ZORYVE skin treatments rose 45% from a year earlier, driven primarily by increased patient demand.…

ARQT +0.7% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 18:16 ETEARNINGS EXPECTED BY FEB 24
Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates

Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.06 per share a year ago.…

ARQT +0.7% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 16:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 24
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update

Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growth Raised 2026 full-year net product …

ARQT +0.7% todayRead at source ↗
● Zacks Investment ResearchOct 28, 2026 · 11:06 ETEARNINGS EXPECTED BY FEB 24
Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth

Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

ARQT +0.7% todayRead at source ↗
● GlobeNewsWireOct 28, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Arcutis Appoints Rob Scott, MD to Board of Directors

Rob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026. Dr. Scott is a global pharma industry leader and pioneer.…

ARQT +0.7% todayRead at source ↗
● GlobeNewsWireOct 27, 2026 · 16:00 ETCOMPANY'S OWN WORDS
Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

WESTLAKE VILLAGE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, t…

ARQT +0.7% todayRead at source ↗
● GlobeNewsWireOct 21, 2026 · 16:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 24
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026

Arcutis today announced that it will report its Q3 2026 financial results and provide a business update after the U.S. financial markets close on Nov 4.…

ARQT +0.7% todayRead at source ↗
● Defense WorldOct 20, 2026 · 04:54 ET
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,728 Shares of Company Stock

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) Director Howard Welgus sold 4,728 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $…

ARQT +0.7% todayRead at source ↗
● BenzingaOct 15, 2026 · 14:06 ET
Why Is Arcutis Biotherapeutics Stock Surging Thursday?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) stock traded higher Thursday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $48 price forecast, citing strong Zoryve sales growth and expansion oppo…

ARQT +0.7% todayRead at source ↗
● GlobeNewsWireOct 9, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to…

ARQT +0.7% todayRead at source ↗
● GlobeNewsWireOct 6, 2026 · 08:19 ETCOMPANY'S OWN WORDS
Arcutis' ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award

Newly created award category highlights innovation in prescription skin treatment ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to …

ARQT +0.7% todayRead at source ↗
● Defense WorldOct 3, 2026 · 04:44 ET
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rated “Moderate Buy” by Wall Street Brokerages

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) have earned an average rating of "Moderate Buy" from the nine brokerages that are currently covering the stock, MarketBeat reports. Three research …

ARQT +0.7% todayRead at source ↗
● GlobeNewsWireOct 2, 2026 · 16:00 ETCOMPANY'S OWN WORDS
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, t…

ARQT +0.7% todayRead at source ↗
● Defense WorldSep 20, 2026 · 05:23 ET
Masaru Matsuda Sells 3,674 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) insider Masaru Matsuda sold 3,674 shares of the business's stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an averag…

ARQT +0.7% todayRead at source ↗
● Zacks Investment ResearchSep 17, 2026 · 11:40 ETEARNINGS EXPECTED BY FEB 24
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?

Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.…

ARQT +0.7% todayRead at source ↗
● Seeking AlphaSep 16, 2026 · 16:31 ET
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

ARQT +0.7% todayRead at source ↗
● GlobeNewsWireSep 4, 2026 · 16:00 ET
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, …

ARQT +0.7% todayRead at source ↗
● GlobeNewsWireSep 2, 2026 · 16:00 ET
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, …

ARQT +0.7% todayRead at source ↗

Expected by Feb 24. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just ARQT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.